Holen Sie sich die Stockscreener-App
6.14
18.76%
0.97
Handel nachbörslich:
6.30
0.16
+2.61%
Schlusskurs vom Vortag:
$5.17
Offen:
$5.1
24-Stunden-Volumen:
4.21M
Relative Volume:
6.52
Marktkapitalisierung:
$220.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+43.46%
1M Leistung:
-66.63%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.0101
$6.74
1-Wochen-Bereich:
$3.85
$6.74
52-Wochen-Spanne:
$3.85
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
1445A SOUTH 50TH STREET, RICHMOND
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
6.14 | 220.11M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Hunterbrook Capital long Bioage Labs, Hunterbrook Media reports - TipRanks
BioAge Labs snags potential half-billion-dollar research deal with NovartisBizwomen - The Business Journals
Aging-focused drug company lands new partner, potential half-billion-dollar payout - The Business Journals
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman - GlobeNewswire
BIOA SHAREHOLDER REPORT: BioAge Labs Investors are Notified the Company is Being Investigated and are Urged to Contact BFA Law - Newsfile
BioAge and Novartis seek drug targets for ageing-related diseases - Yahoo Finance
BioAge, Novartis team up to discover age-related disease targets - MSN
East Bay aging-focused drug company lands new partner, potential half-billion-dollar payout - The Business Journals
BioAge Labs Announces Multi-Year Collaboration with Novartis - Lifespan.io News
BioAge Labs inks $500 million+ collaboration with Novartis - The Pharma Letter
Bioage Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies That Address Age-Related Diseases and Conditions - Marketscreener.com
BioAge Stock Advances 14% On Novartis Research Collaboration - Marketscreener.com
BioAge, Novartis partner on aging-related drug targets - Investing.com
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions - The Manila Times
BIOA SHAREHOLDER NOTICE: BioAge Labs Investors are Alerted - GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kirby McInerney LLP Announces Investigation Against BioAge Labs, Inc. (BIOA) on Behalf of Investors - GlobeNewswire
BIOA INVESTOR NOTICE: BioAge Labs is being Investigated - GlobeNewswire
BIOA INVESTOR NOTICE: BioAge Labs is being Investigated after Discontinuing its Phase 2 Trials -- Contact BFA - EIN News
BIOA INVESTOR ALERT: BioAge Labs Investors are Alerted of Ongoing Investigation into the 76% Stock Drop and are Encouraged to Contact BFA Law - Newsfile
BIOA SHAREHOLDER NOTICE: BioAge Labs is Under Investigation - GlobeNewswire
BIOA SHAREHOLDER NOTICE: BioAge Labs is Under Investigation after the 76% Stock Drop – Contact BFA Law if You Lost Money (NASDAQ:BIOA) - GlobeNewswire Inc.
BIOA SHAREHOLDER NEWS: BioAge Labs, Inc. Investors are Notified of the Ongoing Investigation into the Discontinuation of the Phase 2 Trials – Contact BFA Law - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Stockholders to Connect - AccessWire
BIOA SHAREHOLDER ALERT: BFA Law Notifies BioAge Labs, Inc. Investors to Contact the Firm about its Ongoing Investigation - Newsfile
BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
BIOA INVESTIGATION ALERT: BFA Law Alerts BioAge Labs, Inc. - GlobeNewswire
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - MSN
SHAREHOLDER ALERT: Investigation of BioAge Labs, Inc. (BIOA) Announced by Holzer & Holzer, LLC - GlobeNewswire
BIOA INVESTIGATION: BFA Law Notifies BioAge Labs, Inc. Investors that it is Investigating the Company after the Stock Plummeted 76% and Urges You to Contact the Firm - Newsfile
BioAge Labs stock faces downgrade with no major data expected until 2026 By Investing.com - Investing.com South Africa
BIOA BREAKING NEWS: BFA Law Announces an Investigation into - GlobeNewswire
BIOA Investors Have Opportunity to Join BioAge Labs, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow ... - The Bakersfield Californian
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewswire
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover - EIN News
BioAge Labs stock faces downgrade with no major data expected until 2026 - Investing.com Australia
Jefferies Downgrades BioAge Labs (BIOA) - MSN
Citigroup Downgrades BioAge Labs (BIOA) - MSN
BioAge Labs craters after dropping clinical study on top drug candidate for obesity - Mugglehead
BioAge stock downgraded: Citi sees limited upside after trial discontinuation By Investing.com - Investing.com Australia
BioAge halts obesity trial after safety concerns - Longevity.Technology
BioAge’s Hopes For Combo Obesity Drug Dim Due To Liver Safety - Citeline News & Insights
Richmond-based BioAge sees stock fall over 70% after halting obesity drug clinical trial - The Business Journals
Crude Oil Gains 2%; BioAge Labs Shares Plunge - Inkl
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
BioAge Labs stock under pressure after Phase II trial termination, says Jefferies - Investing.com India
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns - Yahoo Finance
BioAge's chances slimmer after obesity failure - The Pharma Letter
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):